



CIN No : L24239MH1987PLC043662

Date: 14th March, 2022

To,

BSE Ltd.,

Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai - 400 001

Ref.: BSE Scrip Code - 539730

**Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India
(Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In compliance to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we hereunder furnish a press release regarding receipt of approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (CDSCO), India.

Kindly take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited


Fredun Nariman Medhora
Managing Director
DIN: 01745348



Registered Office: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Corporate Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com



PRESS RELEASE

Fredun has Received Approval to manufacture Xenografts for various Dental and Orthopaedic Surgical Applications

Mumbai, India | March 14, 2022

Fredun Pharmaceuticals Limited (BSE: 539730), a pharmaceutical company, has received the approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (CDSCO), India. With this, the Company aims to penetrate the Dental fraternity across India.

Commenting on the recent development, Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals said, "With many doctors now using grafts, we are expanding our product portfolio with this new addition to take advantage of the growing opportunity. With this, we are targeting the Indian Dental fraternity and Orthopaedics who specialize in Humans as well as Veterinary Surgeries. Our objective is to grow this division in H2CY22, after organizing a sale campaign for the said product in India and abroad. We are certain that this development will act as a potential boost to our top-line as well as the net-income in the years to come. We shall share further updates on the official launch and status of the development within a few months."

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited is a pharmaceutical company primarily engaged in the business of pharmaceuticals and healthcare. It offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

For further details, please feel free to contact:

Investor Relations team at Fredun Pharmaceuticals Limited

Fredun Medhora

Managing Director, Fredun Pharmaceuticals Ltd
P: 022-4031 8111
E: investing@fredungroup.com

Registered Office

26, Manoj Industrial Premises,
G.D. Ambedkar Marg, Wadala,
Mumbai – 400 031

Diwakar Pingle

Ernst & Young LLP
P: 022-6129 0000
E: diwakar.pingle@in.ey.com

Corporate Office

'Urmi Estate', 11th Floor,
Ganpatrao Kadam Marg, Lower Parel
(W),
Mumbai – 400 013
Tel. No.: +91 22 4031 8111





Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Fredun and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Fredun, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

A purple circular stamp of Fredun Pharmaceuticals Ltd. Mumbai is positioned to the left of a handwritten signature in blue ink. The stamp contains the text "FREDUN PHARMACEUTICALS LTD." around the perimeter and "MUMBAI" in the center. The signature is a stylized, cursive script.